Prasugrel-, ticagrelor-, or clopidogrel-based dual antiplatelet therapy after acute coronary syndrome: a frequentist network meta-analysis
Dual antiplatelet therapy (DAPT), comprising aspirin and a P2Y12 receptor inhibitor (P2Y12i), remains the cornerstone of secondary prevention of thrombotic complications after acute coronary syndrome (ACS). However, the optimal P2Y12i to use as part of DAPT in patients with ACS remains uncertain. We aimed...